{"id":251114,"date":"2025-06-30T00:00:00","date_gmt":"2025-06-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidon0171-biopharma-malignant-pleural-mesothelioma-epidemiology-2\/"},"modified":"2026-03-31T10:25:55","modified_gmt":"2026-03-31T10:25:55","slug":"epidon0171-biopharma-malignant-pleural-mesothelioma-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidon0171-biopharma-malignant-pleural-mesothelioma-epidemiology-mature-markets\/","title":{"rendered":"Malignant Pleural Mesothelioma &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of malignant pleural mesothelioma (<abbr data-abbreviation-entity=\"8720\" title=\"malignant pleural mesothelioma\">MPM<\/abbr>)\u00a0comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the incidence of <abbr data-abbreviation-entity=\"8720\" title=\"malignant pleural mesothelioma\">MPM<\/abbr>\u00a0for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.<\/p>\n<p>Clarivate Epidemiology&#8217;s <abbr data-abbreviation-entity=\"8720\" title=\"malignant pleural mesothelioma\">MPM<\/abbr>\u00a0forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with <abbr data-abbreviation-entity=\"8720\" title=\"malignant pleural mesothelioma\">MPM<\/abbr>\u00a0per year?<\/li>\n<li>Of all people with <abbr data-abbreviation-entity=\"8720\" title=\"malignant pleural mesothelioma\">MPM<\/abbr>, how many in each country in the major mature pharmaceutical markets have been formally diagnosed?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr data-abbreviation-entity=\"8720\" title=\"malignant pleural mesothelioma\">MPM<\/abbr>\u00a0over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <abbr data-abbreviation-entity=\"10739\" title=\"Microsoft\">MS<\/abbr> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts nine <abbr data-abbreviation-entity=\"8720\" title=\"malignant pleural mesothelioma\">MPM<\/abbr>\u00a0patient populations, as follows:<\/p>\n<ul>\n<li>Diagnosed metastatic recurrent incident cases<\/li>\n<li>Resectable drug-treatable prevalent cases<\/li>\n<li>Diagnosed first-line drug-treatable population<\/li>\n<li>Diagnosed prevalent cases<\/li>\n<li>Unresectable drug-treatable prevalent cases<\/li>\n<li>Resectable non-drug-treatable prevalent cases<\/li>\n<li>Diagnosed unresected incident cases<\/li>\n<li>Diagnosed incident cases<\/li>\n<li>Diagnosed resected incident cases<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251114","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-solid-tumors","biopharma-product-epidemiology","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251114","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251114\/revisions"}],"predecessor-version":[{"id":494129,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251114\/revisions\/494129"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251114"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}